Page last updated: 2024-09-03

gefitinib and u-50488

gefitinib has been researched along with u-50488 in 1 studies

Compound Research Comparison

Studies
(gefitinib)
Trials
(gefitinib)
Recent Studies (post-2010)
(gefitinib)
Studies
(u-50488)
Trials
(u-50488)
Recent Studies (post-2010) (u-50488)
5,2315662,9191,6643209

Protein Interaction Comparison

ProteinTaxonomygefitinib (IC50)u-50488 (IC50)
Delta-type opioid receptorRattus norvegicus (Norway rat)2.15
Kappa-type opioid receptorMus musculus (house mouse)0.0027
Mu-type opioid receptorRattus norvegicus (Norway rat)2.15
Kappa-type opioid receptorRattus norvegicus (Norway rat)0.7171
Kappa-type opioid receptorCavia porcellus (domestic guinea pig)0.0958
Kappa-type opioid receptorHomo sapiens (human)0.0537

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hosoya, T; Imai, S; Kuzumaki, N; Morita, H; Nagasawa, A; Nagase, H; Narita, M; Okada, Y; Okano, H; Okano, HJ; Suzuki, A; Suzuki, T; Yamamizu, K; Yamashita, JK1

Other Studies

1 other study(ies) available for gefitinib and u-50488

ArticleYear
Effect of κ-opioid receptor agonist on the growth of non-small cell lung cancer (NSCLC) cells.
    British journal of cancer, 2012, Mar-13, Volume: 106, Issue:6

    Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Mutation, Missense; Naltrexone; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, Opioid, kappa; Signal Transduction; STAT3 Transcription Factor

2012